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    Diabetes, Osteoporosis, Bone Fracture, Bone Mineral Density (BMD), Insulin Therapy 
 
Abbreviations 
    BMD: Bone Mineral Density 
 
    Diabetes and osteoporosis have been highly 
prevalent and substantially contributed to the disability 
burden across the world [1] T1DM patients have 
decreased Bone Mineral Density (BMD), while T2DM 
patients have often increased BMD [2]. In T2DM, 
obesity increases bone mass but increases fracture 
rate. This mechanism is due to impaired osteogenesis 
accompanied by deterioration of bone quality due to 
increased oxidative stress, deterioration of bone 
microstructure, promotion of cortical bone porosity, 
decrease in osteoblast count due to insulin deficiency 
and continuous exposure to high glucose 
concentration. Among them, the most common 
vertebral fractures are accompanied with increased 
risk of mortality [3].  
 
    From the point of general  practice,  annual  study of 
ground-level fall was conducted for 1 year with 596 
patients [4]. As a result, 23% were aged <15 years, 
while 29.5% was >60 years. The elderly showed a 
higher odds ratio 2.51 of sustaining a fracture of a 
dislocation, and the ratio necessary for major surgical 
operation was 19.9%.  
 
    Concerning the osteopenia in diabetes, several 
mechanisms are involved. Malnutrition progresses 
from decreased exercise due to diabetic neuropathy 
and cerebrovascular disorder, and absorption disorder 
due to diabetic gastrointestinal disorder, followed by 
osteopenia. In particular, sarcopenia/flail is a 
latecomer to diabetes and causes a decrease in cortical 
bone width [5], which can bring proximal femur 
fractures. It also increases the fracture rate through 
decreased physical activity and mechanical  stimulation  
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    Diabetes and osteoporosis have been highly prevalent. Insulin therapy may increase risk of fracture. 
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of bones, increased risk of falls and fractures of the 
proximal femur during falls due to gluteal muscular 
atrophy. 
 
    The relationship between vertebral fracture risk and 
diabetes was studied [1]. It included two recent studies 
with the result of the efficacy of teriparatide and 
denosumab for reducing vertebral fracture risk in 
T2DM cases [6,7]. Teriparatide has been effective for 
reducing fracture risks. From 4 observational studies 
(n=8828), fracture rates were compared in 4 aspects 
[7]. They showed that clinical vertebral fractures 
(CVF), nonvertebral fractures (NVF), clinical fractures 
(CVF & NVF), hip fracture was 62%, 43%, 50%, 56%, 
respectively (all p<0.005).  
 
    The relationship between T2DM and enhanced risk 
of bone fracture was investigated, including 138,690 
cases from 7 studies [8]. Insulin therapy totally 
increased risk of fracture for Relative Ratio (RR) 1.24. 
Results of RR were that men 1.04, female 1.22, hip 1.18, 
vertebrae 1.28, non-vertebrae 1.06, Europe 1.16, North 
America 1.24, Asia 1.34. Thus, insulin therapy 
increased the fracture risk for T2DM in comparison 
with oral hypoglycemic agents (OHAs).  
 
    For cohort study, 216,624 patients were followed for 
5 years [9]. The results were that 63% cases changed 
treatments, and among them 21% changed to insulin 
(n=28,420). Hazard ratio of fractures was 1.5, with 
1.6/1.8 of hip/vertebral fractures, respectively. The 
events mainly occurred the first 2 months after 
switching. Consequently, elevated hypoglycemic risk 
may be involved in greater episodes of fractures [9]. 
Furthermore, some advantageous perspectives include 
the clinical situation related to medication switch, 
complication risks and adherent influence to the 
prescription [10]. 
 
    One of the common GLP-1RAs would be liraglutide, 
which showed unchanged bone resorption for T2DM 
[11].  In summary, recent topics concerning diabetes 
and osteoporosis are described. This will hopefully 
become a suggestion for clinical practice. 
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